How can the risk that orphan drugs present to budgets be managed better?

Editorial

. 2010 Aug;32(9):1640-1.

doi: 10.1016/j.clinthera.2010.08.007.

Editorial

Ciaran O'Neill. Clin Ther. 2010 Aug.

. 2010 Aug;32(9):1640-1.

doi: 10.1016/j.clinthera.2010.08.007.

No abstract available

Comment on

Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
Vegter S, Rozenbaum MH, Postema R, Tolley K, Postma MJ. Vegter S, et al. Clin Ther. 2010 Aug;32(9):1651-61. doi: 10.1016/j.clinthera.2010.08.006. Clin Ther. 2010. PMID: 20974323

Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
Vegter S, Rozenbaum MH, Postema R, Tolley K, Postma MJ. Vegter S, et al. Clin Ther. 2010 Aug;32(9):1651-61. doi: 10.1016/j.clinthera.2010.08.006. Clin Ther. 2010. PMID: 20974323
[Medication: 15 years 'EU-directive orphan drugs'].
Dooms M. Dooms M. Bull Cercle Benelux Hist Pharm. 2015 Mar;(128):21-6. Bull Cercle Benelux Hist Pharm. 2015. PMID: 26137669 Dutch.
Access to orphan drugs in Europe: current and future issues.
Michel M, Toumi M. Michel M, et al. Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):23-9. doi: 10.1586/erp.11.95. Expert Rev Pharmacoecon Outcomes Res. 2012. PMID: 22280193
[Authorization and reimbursement of orphan drugs in an international comparison].
Roll K, Stargardt T, Schreyögg J. Roll K, et al. Gesundheitswesen. 2011 Aug;73(8-9):504-14. doi: 10.1055/s-0030-1262864. Epub 2010 Sep 16. Gesundheitswesen. 2011. PMID: 20848380 Review. German.
Economic considerations in the provision of treatments for rare diseases.
McCabe C, Edlin R, Round J. McCabe C, et al. Adv Exp Med Biol. 2010;686:211-22. doi: 10.1007/978-90-481-9485-8_13. Adv Exp Med Biol. 2010. PMID: 20824448 Review.